PMV Pharma's PC14586 shows 30% partial response in higher dose cohorts at ASCO

PMV Pharmaceuticals, Inc.

Abstract reports 3/10 (30%) partial responses in patients treated in higher dose cohorts of Phase 1/2 PYNNACLE trial.
Data from 29 patients (21 evaluable) across multiple tumor types with p53 Y220C mutation; safety profile well-tolerated.
Dose-proportional increases in Cmax and AUC observed; updated data to be presented in oral session on June 7, 2022.
Company to host investor webcast on June 7 at 6:30 PM CDT to review data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.